EUROFINS CEREP-REGR (ALECR.PA) Stock Price, Forecast & Analysis
EPA:ALECR • FR0013256518
ALECR.PA Key Statistics, Chart & Performance
The current stock price of ALECR.PA is 17400 EUR. In the past month the price increased by 10.13%. In the past year, price increased by 176.19%.
ALECR.PA Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ALECR.PA. When comparing the yearly performance of all stocks, ALECR.PA is one of the better performing stocks in the market, outperforming 97.14% of all stocks.
ALECR.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ALECR.PA. ALECR.PA has an average financial health and profitability rating.
ALECR.PA Financial Highlights
Over the last trailing twelve months ALECR.PA reported a non-GAAP Earnings per Share(EPS) of 715. The EPS decreased by -6.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 16.86% | ||
| ROA | 9.29% | ||
| ROE | 10.82% | ||
| Debt/Equity | 0 |
ALECR.PA Forecast & Estimates
ALECR.PA Ownership
ALECR.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| SRT3 | SARTORIUS AG-VORZUG | 39.5 | 17.896B | ||
| DIM | SARTORIUS STEDIM BIOTECH | 34.25 | 17.787B | ||
| 56S1 | SARTORIUS STEDIM BIOTECH | 33.94 | 17.626B | ||
| SRT | SARTORIUS AG | 32.59 | 14.766B | ||
| QIA | QIAGEN N.V. | 17.9 | 8.443B | ||
| 1SXP | SCHOTT PHARMA AG& CO KGAA | 13.46 | 2.298B | ||
| EVT | EVOTEC SE | N/A | 2.168B | ||
| GXI | GERRESHEIMER AG | 6.81 | 705.998M | ||
| FF | FINE FOODS & PHARMACEUTICALS | 16.41 | 254.242M |
Related stock screener links
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About ALECR.PA
Company Profile
Eurofins-Cerep SA engages in the provision of preclinical drug research services. The company is headquartered in Celle-Levescault, Nouvelle-Aquitaine and currently employs 207 full-time employees. The company went IPO on 2010-03-19. The Company, using its BioPrint technology systems that analyzes pharmaceutical drugs on the market, those that have been withdrawn, and those that failed in the development stages, builds up predictive models of the potential of new drugs. These predictions are based on the drugs' chemical structure and their performance in vitro. The firm then offers solutions to the pharmaceutical and biotechnology sectors on reducing time and costs in the early stages of the drug development process. Clients can also gain access to some of the Company's technology by subscribing to BioPrint. The Company’s maximum revenue is generated through Exports accounts.
Company Info
EUROFINS CEREP-REGR
Le Bois l'Eveque
Celle-Levescault NOUVELLE-AQUITAINE FR
Employees: 218
Phone: 33549893000
EUROFINS CEREP-REGR / ALECR.PA FAQ
What does EUROFINS CEREP-REGR do?
Eurofins-Cerep SA engages in the provision of preclinical drug research services. The company is headquartered in Celle-Levescault, Nouvelle-Aquitaine and currently employs 207 full-time employees. The company went IPO on 2010-03-19. The Company, using its BioPrint technology systems that analyzes pharmaceutical drugs on the market, those that have been withdrawn, and those that failed in the development stages, builds up predictive models of the potential of new drugs. These predictions are based on the drugs' chemical structure and their performance in vitro. The firm then offers solutions to the pharmaceutical and biotechnology sectors on reducing time and costs in the early stages of the drug development process. Clients can also gain access to some of the Company's technology by subscribing to BioPrint. The Company’s maximum revenue is generated through Exports accounts.
Can you provide the latest stock price for EUROFINS CEREP-REGR?
The current stock price of ALECR.PA is 17400 EUR. The price increased by 9.43% in the last trading session.
Does EUROFINS CEREP-REGR pay dividends?
ALECR.PA does not pay a dividend.
What is the ChartMill rating of EUROFINS CEREP-REGR stock?
ALECR.PA has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the PE ratio for ALECR stock?
The PE ratio for EUROFINS CEREP-REGR (ALECR.PA) is 24.34. This is based on the reported non-GAAP earnings per share of 715 and the current share price of 17400 EUR.
Can you provide the ownership details for ALECR stock?
You can find the ownership structure of EUROFINS CEREP-REGR (ALECR.PA) on the Ownership tab.